Oxaliplatin API (Johnson Matthey) – Glass Contamination (2019)
Class II: A situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Class II recall indicates potential for temporary health effects.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Oxaliplatin Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceutical Materials 2003 Nolte Drive, West Deptford, NJ 08066-1742 (856) 384-7001, NDC 49821-0075-XX
Brand
Johnson Matthey Inc.
Lot Codes / Batch Numbers
Lot #: B0126-170701, B0126-170802, Exp. Sep 2022, B0126-180401, Exp. May 2023, B0126-180702, B0126-180803, Exp. Oct 2023
Products Sold
Lot #: B0126-170701; B0126-170802; Exp. Sep 2022; B0126-180401, Exp. May 2023; B0126-180702, B0126-180803, Exp. Oct 2023
Johnson Matthey Inc. is recalling Oxaliplatin Active Pharmaceutical Ingredient, Johnson Matthey Pharmaceutical Materials 2003 Nolte Dr due to cGMP Deviations: Potential glass contamination. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
cGMP Deviations: Potential glass contamination
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026